Q1 Earnings Estimate for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Investment analysts at HC Wainwright dropped their Q1 2026 earnings per share (EPS) estimates for shares of Genmab A/S in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.34 per share for the quarter, down from their prior estimate of $0.36. HC Wainwright currently has a “Buy” rating and a $41.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

GMAB has been the subject of a number of other reports. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research report on Tuesday, September 23rd. Wall Street Zen downgraded shares of Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Zacks Research cut Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 31st. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Genmab A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.75.

Genmab A/S Trading Up 0.5%

Shares of Genmab A/S stock opened at $30.47 on Wednesday. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $33.65. The firm has a market capitalization of $19.56 billion, a P/E ratio of 12.97, a P/E/G ratio of 1.58 and a beta of 0.96. The business has a fifty day simple moving average of $29.85 and a two-hundred day simple moving average of $24.66.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $975.40 million. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%. Genmab A/S has set its FY 2025 guidance at EPS.

Institutional Trading of Genmab A/S

A number of large investors have recently made changes to their positions in the stock. Envestnet Asset Management Inc. lifted its position in Genmab A/S by 1.7% during the first quarter. Envestnet Asset Management Inc. now owns 736,326 shares of the company’s stock valued at $14,417,000 after purchasing an additional 12,545 shares during the period. DDD Partners LLC raised its stake in Genmab A/S by 165.9% during the 1st quarter. DDD Partners LLC now owns 601,050 shares of the company’s stock valued at $11,769,000 after buying an additional 374,976 shares during the last quarter. Grandfield & Dodd LLC lifted its holdings in shares of Genmab A/S by 18.3% during the 1st quarter. Grandfield & Dodd LLC now owns 39,893 shares of the company’s stock valued at $781,000 after buying an additional 6,160 shares during the period. Wealth Alliance LLC purchased a new position in shares of Genmab A/S in the 1st quarter worth $277,000. Finally, Gallacher Capital Management LLC grew its holdings in shares of Genmab A/S by 6.8% in the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock worth $281,000 after acquiring an additional 915 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.